Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

The Boston-based company’s new drug, a twice-daily pill known in development as suzetrigine, will be marketed under the brand name Journavx. “Today’s approval is an important public health ...

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 years. Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Sold as Journavx, the drug received U.S. approval in late January as a treatment for the short-lived “acute” pain typically felt after an operation or accident. Journavx works differently than ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

New Orleans-based investment network Gulf South Angels is investing in non-opioid pain drug startup South Rampart Pharma as ...

The medication, called Journavx, got US regulatory clearance in January. The financial success of new drugs largely depends on how they’re treated by pharmacy benefit managers that determine ...